Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 08/09/17 at 10:26am

This week saw a number of hard-hitting stories hit the headlines that are sure to have resonant consequences. Following the "historic" approval of Novartis' CAR T therapy by the FDA - the first of its kind - last week, the FDA called for a clinical trial of the treatment to be placed on hold after the first instance of CAR-T associated death, which could have big implications for the future of the technology.

Novartis also announced that CEO Joe Jimenez will be ending his decade-long tenure at the company next year, stepping down to be succeeded by current Global Head of Drug Development and Chief Medical Officer Vasant Narasimhan.

But the biggest draw this week was our feature on the fallout of the Charlottesville violence, and what its means for the future of President Trump's relationship with pharma and wider industry.

Check out the week's ten most popular articles on Pharmafile.com now!

10. Amgen and AstraZeneca's experimental drug cuts asthma exacerbations by up to 71%

An anti-TSLP monoclonal antibody jointly developed by Amgen and AstraZeneca has met its primary endpoint in Phase 2b trials, demonstrating a significant reduction in annual exacerbation rates in patients with severe, uncontrolled asthma.

9. Takeda partners up to develop "next generation" CAR T solid tumour therapy

Takeda is set to partner with Noile-Immune Biotech in the development of a “next generation” chimeric antigen receptor T-cell (CAR T) therapy for effectively treating solid tumours, it has emerged.

8. Sanofi backs out of controversial Zika vaccine project

Sanofi’s development of a Zika vaccine, alongside the US’s BARDA, has hit the headlines quite a few times since the deal was announced, not due to successes but controversies, and now Sanofi has pulled the plug.

7. Novartis CEO Jimenez announces retirement in 2018

Novartis has announced that its Chief Executive, Joe Jimenez, is set to retire next year. In his place, Vasant Narasimhan, its Global Head of Drug Development and Chief Medical Officer, will step up to lead the company.

6. Novartis celebrates success of Gilenya in paediatric multiple sclerosis

Novartis has announced results of its Phase 3 study investigating the safety and efficacy of Gilenya (fingolimod), finding that the drug met its primary endpoint in the treatment of multiple sclerosis (MS) in children and adolescent.

5. Asthma drugs reduce Parkinson's risk by 50%, decade-long study finds

A study has revealed that commonly prescribed asthma drugs have the ability to reduce the risk of developing Parkinson’s disease by around 50%.

4. NICE rejects AstraZeneca's breast cancer drug Faslodex

NICE has announced its decision to not recommend AstraZeneca’s drug Faslodex (fulvestrant) in women with breast cancer over doubts concerning its efficacy compared to existing treatments.

3. Patently problematic? The impact of the Eli Lilly/Actavis intellectual property battle

Fiona Stevens, Partner at Gill, Jennings and Every, discusses the UK Supreme Court's decision on Eli Lilly v Actavis [2017] UKSC 48, and why the ruling was problematic within the IP world.

2. FDA halts trial after first CAR T-associated patient death

A French biopharma firm has received an order from the FDA to halt its study of CAR T therapy UCART123 after a 78-year old patient died as a result of a toxic reaction to the treatment.

1, Has Trump's power over pharma come to an end after Charlottesville?

Pivotal moment for the relationship between Donald Trump and industry as MSD CEO Kenneth Frazier leads the collapse of the President's manufacturing committee.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches